Livzon Pharma Confirms Stable Share Capital and Adequate Public Float for March 2026

Bulletin Express04-01

Livzon Pharmaceutical Group Inc. (Livzon Pharma) filed its Monthly Return on Movements in Securities for the period ended 31 March 2026, showing no change in either authorised or issued share capital.

• Authorised/Registered Capital – H shares: 299.81 million shares at RMB 1 par value. – A shares: 588.10 million shares at RMB 1 par value. – Combined total: 887.91 million shares, unchanged from the previous month.

• Issued Shares and Treasury Position – H shares in issue: 299.81 million; treasury shares: 0. – A shares in issue: 588.10 million; treasury shares: 0. – No issuance, cancellation, or repurchase activity occurred during the month.

• Public Float – The company confirmed compliance with the Hong Kong Stock Exchange’s minimum public-float requirement of 5% for its H-share class as of 31 March 2026.

• Capital Instruments and Corporate Actions – The filing reports no outstanding share options, warrants, convertible securities, HDRs, or other equity-linked instruments.

The March 2026 return indicates a stable capital structure, with Livzon Pharma maintaining both its share count and full adherence to listing rule obligations.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1134864646?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-01 17:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1134864646","market":"hk","top_or_hot":-1,"title":"Livzon Pharma Confirms Stable Share Capital and Adequate Public Float for March 2026","media":"Bulletin Express","content":"<p>Livzon Pharmaceutical Group Inc. (Livzon Pharma) filed its Monthly Return on Movements in Securities for the period ended 31 March 2026, showing no change in either authorised or issued share capital.</p>\n<p>• Authorised/Registered Capital  \n  – H shares: 299.81 million shares at RMB 1 par value.  \n  – A shares: 588.10 million shares at RMB 1 par value.  \n  – Combined total: 887.91 million shares, unchanged from the previous month.</p>\n<p>• Issued Shares and Treasury Position  \n  – H shares in issue: 299.81 million; treasury shares: 0.  \n  – A shares in issue: 588.10 million; treasury shares: 0.  \n  – No issuance, cancellation, or repurchase activity occurred during the month.</p>\n<p>• Public Float  \n  – The company confirmed compliance with the Hong Kong Stock Exchange’s minimum public-float requirement of 5% for its H-share class as of 31 March 2026.</p>\n<p>• Capital Instruments and Corporate Actions  \n  – The filing reports no outstanding share options, warrants, convertible securities, HDRs, or other equity-linked instruments.</p>\n<p>The March 2026 return indicates a stable capital structure, with Livzon Pharma maintaining both its share count and full adherence to listing rule obligations.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Livzon Pharma Confirms Stable Share Capital and Adequate Public Float for March 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLivzon Pharma Confirms Stable Share Capital and Adequate Public Float for March 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-04-01 17:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Livzon Pharmaceutical Group Inc. (Livzon Pharma) filed its Monthly Return on Movements in Securities for the period ended 31 March 2026, showing no change in either authorised or issued share capital.</p>\n<p>• Authorised/Registered Capital  \n  – H shares: 299.81 million shares at RMB 1 par value.  \n  – A shares: 588.10 million shares at RMB 1 par value.  \n  – Combined total: 887.91 million shares, unchanged from the previous month.</p>\n<p>• Issued Shares and Treasury Position  \n  – H shares in issue: 299.81 million; treasury shares: 0.  \n  – A shares in issue: 588.10 million; treasury shares: 0.  \n  – No issuance, cancellation, or repurchase activity occurred during the month.</p>\n<p>• Public Float  \n  – The company confirmed compliance with the Hong Kong Stock Exchange’s minimum public-float requirement of 5% for its H-share class as of 31 March 2026.</p>\n<p>• Capital Instruments and Corporate Actions  \n  – The filing reports no outstanding share options, warrants, convertible securities, HDRs, or other equity-linked instruments.</p>\n<p>The March 2026 return indicates a stable capital structure, with Livzon Pharma maintaining both its share count and full adherence to listing rule obligations.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01513","symbol_name":"丽珠医药","start_time":0,"source_url":"","article_id":"1134864646","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1134864646","pubTimestamp":1775036870,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Livzon Pharmaceutical Group Inc. (Livzon Pharma) filed its Monthly Return on Movements in Securities for the period ended 31 March 2026, showing no change in either authorised or issued share...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01513":"丽珠医药"},"translate_title":"丽珠医药确认2026年3月股本稳定且公众持股量充足","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01513":1},"content_text":"Livzon Pharmaceutical Group Inc. (Livzon Pharma) filed its Monthly Return on Movements in Securities for the period ended 31 March 2026, showing no change in either authorised or issued share capital.\n• Authorised/Registered Capital  \n  – H shares: 299.81 million shares at RMB 1 par value.  \n  – A shares: 588.10 million shares at RMB 1 par value.  \n  – Combined total: 887.91 million shares, unchanged from the previous month.\n• Issued Shares and Treasury Position  \n  – H shares in issue: 299.81 million; treasury shares: 0.  \n  – A shares in issue: 588.10 million; treasury shares: 0.  \n  – No issuance, cancellation, or repurchase activity occurred during the month.\n• Public Float  \n  – The company confirmed compliance with the Hong Kong Stock Exchange’s minimum public-float requirement of 5% for its H-share class as of 31 March 2026.\n• Capital Instruments and Corporate Actions  \n  – The filing reports no outstanding share options, warrants, convertible securities, HDRs, or other equity-linked instruments.\nThe March 2026 return indicates a stable capital structure, with Livzon Pharma maintaining both its share count and full adherence to listing rule obligations.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1134864646","isCrawlerRequest":true}